ELI Lilly (LLY) stock
Last close $1,351.12 on 2026-11-19 (-2.29%) · Sector: Healthcare
Eli Lilly and Company is an American drugmaker based in Indianapolis, Indiana, with offices in 18 countries. It makes money mainly by developing and selling prescription medicines to patients, insurers, and healthcare systems around the world.
Revenue has grown fast, up 45.5% over the past year, and the stock returned 29.5% over the last year versus 9.7% for the S&P 500, so it has beaten the broader market. Shares are trading 7.0% above their 50-day average and 21.0% above their 200-day average, though they remain 8.4% below their 52-week high. The stock rose the day after all four recent earnings reports, but it has also swung far more than the market, and insiders recorded several share sales in recent months.
Key numbers
- Market cap: $1,207.1B
- Revenue (last 12 months): $86.46B
- Revenue growth: +45.5%
- Gross margin: 83.5%
- P/E: 43.9
- P/S: 14.0
- Debt to equity: 1.17
- Current ratio: 1.39
Quality score
Overall 43/100 · growth 66 · profitability None · financial health 24 · value 40
Performance and risk
1-year return +29.5% vs S&P 500 +9.7% · volatility 35.5% (S&P 500 13.8%) · largest drop -23.3% · beta 0.34
Stock move the day after earnings
- 2026-02-04: +10.3%
- 2026-04-30: +9.8%
- 2026-08-05: +4.9%
- 2026-10-29: +6.6%
Congress trades (90 days)
1 buys, 2 sells
Insider trades (12 months)
Bought $0.0M · sold $1,029.8M
LLY stock research · LLY options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.